Cargando…
Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma
Gene expression profiling has been vastly used to extract the genes that can predict the clinical outcome in patients with diverse cancers, including diffuse large B-cell lymphoma (DLBCL). With the aid of bioinformatics and computational analysis on gene expression data, various prognostic gene sign...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548397/ https://www.ncbi.nlm.nih.gov/pubmed/34702929 http://dx.doi.org/10.1038/s41598-021-00746-0 |
_version_ | 1784590564600053760 |
---|---|
author | Zamani-Ahmadmahmudi, Mohamad Nassiri, Seyed Mahdi Asadabadi, Amir |
author_facet | Zamani-Ahmadmahmudi, Mohamad Nassiri, Seyed Mahdi Asadabadi, Amir |
author_sort | Zamani-Ahmadmahmudi, Mohamad |
collection | PubMed |
description | Gene expression profiling has been vastly used to extract the genes that can predict the clinical outcome in patients with diverse cancers, including diffuse large B-cell lymphoma (DLBCL). With the aid of bioinformatics and computational analysis on gene expression data, various prognostic gene signatures for DLBCL have been recently developed. The major drawback of the previous signatures is their inability to correctly predict survival in external data sets. In other words, they are not reproducible in other datasets. Hence, in this study, we sought to determine the gene(s) that can reproducibly and robustly predict survival in patients with DLBCL. Gene expression data were extracted from 7 datasets containing 1636 patients (GSE10846 [n = 420], GSE31312 [n = 470], GSE11318 [n = 203], GSE32918 [n = 172], GSE4475 [n = 123], GSE69051 [n = 157], and GSE34171 [n = 91]). Genes significantly associated with overall survival were detected using the univariate Cox proportional hazards analysis with a P value < 0.001 and a false discovery rate (FDR) < 5%. Thereafter, significant genes common between all the datasets were extracted. Additionally, chromosomal aberrations in the corresponding region of the final common gene(s) were evaluated as copy number alterations using the single nucleotide polymorphism (SNP) data of 570 patients with DLBCL (GSE58718 [n = 242], GSE57277 [n = 148], and GSE34171 [n = 180]). Our results indicated that reticulon family gene 1 (RTN1) was the only gene that met our rigorous pipeline criteria and associated with a favorable clinical outcome in all the datasets (P < 0.001, FDR < 5%). In the multivariate Cox proportional hazards analysis, this gene remained independent of the routine international prognostic index components (i.e., age, stage, lactate dehydrogenase level, Eastern Cooperative Oncology Group [ECOG] performance status, and number of extranodal sites) (P < 0.0001). Furthermore, no significant chromosomal aberration was found in the RTN1 genomic region (14q23.1: Start 59,595,976/End 59,870,966). |
format | Online Article Text |
id | pubmed-8548397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-85483972021-10-27 Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma Zamani-Ahmadmahmudi, Mohamad Nassiri, Seyed Mahdi Asadabadi, Amir Sci Rep Article Gene expression profiling has been vastly used to extract the genes that can predict the clinical outcome in patients with diverse cancers, including diffuse large B-cell lymphoma (DLBCL). With the aid of bioinformatics and computational analysis on gene expression data, various prognostic gene signatures for DLBCL have been recently developed. The major drawback of the previous signatures is their inability to correctly predict survival in external data sets. In other words, they are not reproducible in other datasets. Hence, in this study, we sought to determine the gene(s) that can reproducibly and robustly predict survival in patients with DLBCL. Gene expression data were extracted from 7 datasets containing 1636 patients (GSE10846 [n = 420], GSE31312 [n = 470], GSE11318 [n = 203], GSE32918 [n = 172], GSE4475 [n = 123], GSE69051 [n = 157], and GSE34171 [n = 91]). Genes significantly associated with overall survival were detected using the univariate Cox proportional hazards analysis with a P value < 0.001 and a false discovery rate (FDR) < 5%. Thereafter, significant genes common between all the datasets were extracted. Additionally, chromosomal aberrations in the corresponding region of the final common gene(s) were evaluated as copy number alterations using the single nucleotide polymorphism (SNP) data of 570 patients with DLBCL (GSE58718 [n = 242], GSE57277 [n = 148], and GSE34171 [n = 180]). Our results indicated that reticulon family gene 1 (RTN1) was the only gene that met our rigorous pipeline criteria and associated with a favorable clinical outcome in all the datasets (P < 0.001, FDR < 5%). In the multivariate Cox proportional hazards analysis, this gene remained independent of the routine international prognostic index components (i.e., age, stage, lactate dehydrogenase level, Eastern Cooperative Oncology Group [ECOG] performance status, and number of extranodal sites) (P < 0.0001). Furthermore, no significant chromosomal aberration was found in the RTN1 genomic region (14q23.1: Start 59,595,976/End 59,870,966). Nature Publishing Group UK 2021-10-26 /pmc/articles/PMC8548397/ /pubmed/34702929 http://dx.doi.org/10.1038/s41598-021-00746-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zamani-Ahmadmahmudi, Mohamad Nassiri, Seyed Mahdi Asadabadi, Amir Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma |
title | Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma |
title_full | Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma |
title_fullStr | Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma |
title_full_unstemmed | Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma |
title_short | Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma |
title_sort | prognostic efficacy of the rtn1 gene in patients with diffuse large b-cell lymphoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548397/ https://www.ncbi.nlm.nih.gov/pubmed/34702929 http://dx.doi.org/10.1038/s41598-021-00746-0 |
work_keys_str_mv | AT zamaniahmadmahmudimohamad prognosticefficacyofthertn1geneinpatientswithdiffuselargebcelllymphoma AT nassiriseyedmahdi prognosticefficacyofthertn1geneinpatientswithdiffuselargebcelllymphoma AT asadabadiamir prognosticefficacyofthertn1geneinpatientswithdiffuselargebcelllymphoma |